About this event
The global obesity epidemic and the surge in cardiometabolic diseases are pressing challenges that demand innovative solutions. According to the World Health Organization, obesity has nearly tripled since 1975 and is a major risk factor for chronic conditions such as type 2 diabetes, cardiovascular diseases, and certain cancers [1]. Effective management of these conditions thus requires innovative approaches that can seamlessly integrate into patients’ daily lives. Autoinjectors have emerged as a critical solution to deliver treatments for cardiometabolic diseases, providing patients with convenient and reliable ways to manage their conditions from the comfort of their homes.
In this exclusive video, SHL’s Senior Manager of Portfolio Strategy and Customer Solutions, Lars Berger discusses how SHL leverages its experience in drug-device development to support cardiometabolic care. Since 2016, SHL Medical has supported the launch of at least six combination products indicated for cardiometabolic diseases. Of these, the Molly® modular platform autoinjectors have been an integral part of accelerating the commercialization of formulations for this therapy area.
Key highlights:
- Patient-centric autoinjector technologies:
Find out how SHL’s Molly autoinjectors support cardiometabolic care at the present time.
- Extensive experience:
More insights on SHL Medical’s proven track record in launching combination products for cardiometabolic diseases.
- Scalable manufacturing:
Discover how SHL’s vertically integrated manufacturing capabilities keep us ahead in the rapidly evolving field of cardiometabolic care.
- Commitment to patients:
Learn more about SHL’s dedication to providing the best user experience for cardiometabolic patients through its extensive research and development efforts.
Reference:
- World Health Organization: WHO. (2024, March 1). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
SHL Medical
Enable patients' independenceAs a pioneer in innovative self-injection solutions, SHL Medical enables patients’ independence through partnerships with leading pharma and biotech companies. We design, develop, and manufacture high-quality solutions, leveraging our vertically integrated capabilities and regulatory expertise.
